Lupin announced that it has received tentative approval for its Efinaconazole Topical Solution, 10%, from the United States Food and Drug Administration, to market a generic equivalent of Jublia Topical Solution, 10%, of Bausch Health Americas, Inc. Efinaconazole Topical Solution, 10%, is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes. Efinaconazole Topical Solution, 10%, (RLD: Jublia) had estimated annual sales of $222.9 million in the U.S. (IQVIA MAT September 2020). The announcement was made after market hours on Thursday, 24 December 2020. Shares of Lupin rose 1.37% to settle at Rs 976.15 on Thursday. The stock hit a 52-week high of Rs 1121.85 on 18 September 2020. The stock hit a 52-week low of Rs 505 on 13 March 2020.